Personalis, Inc. (PSNL) News
Track canonical SquawkNews coverage tagged to PSNL, Personalis, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Bulls and Bears: IBM, Super Micro, Tesla
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks endured a difficult week as a renewed surge in oil prices and disappointing reactions
MACRO | Jul 25, 2026, 12:00 PM UTC
L
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
On Monday, Tempus AI, Inc. (NASDAQ: TEM ) agreed to acquire Personalis, Inc. (NASDAQ: PSNL ), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased earl
RATES | Jul 21, 2026, 06:52 PM UTC
H
What You Missed On Wall Street On Monday
The major averages closed lower, with the Nasdaq closing near flat, as stocks looked to rebound from last week's technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether the
EARNINGS | Jul 20, 2026, 08:16 PM UTC
L
TEM PSNL TEM agrees to acquire remaining 80% of PSNL for $16.25/share in deal valued at $1.5B, Strategically, it makes sense to US given the
TEM PSNL TEM agrees to acquire remaining 80% of PSNL for $16.25/share in deal valued at $1.5B, Strategically, it makes sense to US given the long working relationship and complementary offerings @ MSCO
MNA | Jul 20, 2026, 07:35 PM UTC
H
Midday Fly By: Domino's reports mixed Q2, Tempus AI to acquire Personalis
The major averages were mixed near noon as stocks look to rebound from last week's technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether the AI-driven rally regains momen
EQUITY | Jul 20, 2026, 04:00 PM UTC
L
PSNL resumes trading, -1% after M&A headlines with TEM, -5%
PSNL resumes trading, -1% after M&A headlines with TEM, -5%
MNA | Jul 20, 2026, 12:56 PM UTC
L
PSNL TEM Tempus AI Inc - cash consideration will be financed with cash on hand and borrowings under company's then existing credit facilitie
PSNL TEM Tempus AI Inc - cash consideration will be financed with cash on hand and borrowings under company's then existing credit facilities Tempus AI Inc - maximum exchange ratio set at 0.3356 Tempus AI shares per Pers
EQUITY | Jul 20, 2026, 12:31 PM UTC
L
PSNL TEM Tempus - consideration structured as 100% stock, cash option capped at 50%
PSNL TEM Tempus - consideration structured as 100% stock, cash option capped at 50%
EQUITY | Jul 20, 2026, 12:30 PM UTC
L
PSNL TEM Tempus to acquire Personalis, more tightly integrating Molecular residual disease (mrd) into its AI-enabled Precision Oncology plat
PSNL TEM Tempus to acquire Personalis, more tightly integrating Molecular residual disease (mrd) into its AI-enabled Precision Oncology platform 20 Jul 2026 08:30:05 am - Personalis - deal valued at $1.50B, Personalis sh
MNA | Jul 20, 2026, 12:30 PM UTC
L
PSNL shares add +3% premarket after rising late Thursday following a report (by Street insider) indicating that the company is exploring a p
PSNL shares add +3% premarket after rising late Thursday following a report (by Street insider) indicating that the company is exploring a potential sale after receiving takeover interest from MRK and two other bidders.
EARNINGS | Jul 17, 2026, 01:10 PM UTC
L
PSNL PT raised from $12 to $17, maintains Buy @ Needham
PSNL PT raised from $12 to $17, maintains Buy @ Needham
EQUITY | Jul 17, 2026, 11:29 AM UTC
L
PSNL premarket highs +4% after M&A speculation late yesterday
PSNL premarket highs +4% after M&A speculation late yesterday
MNA | Jul 17, 2026, 11:12 AM UTC
L
PSNL paring losses, jump to highs after Street Insider report citing sources of exploring sale
PSNL paring losses, jump to highs after Street Insider report citing sources of exploring sale
EQUITY | Jul 16, 2026, 07:36 PM UTC
L
PSNL MRK Personalis (NASDAQ: PSNL) has attracted takeover interest from Pharmaceutical giant Merck (NYSE: MRK) and at least two other suitor
PSNL MRK Personalis (NASDAQ: PSNL) has attracted takeover interest from Pharmaceutical giant Merck (NYSE: MRK) and at least two other suitors, according to a source. As a result of the overtures, the Precision Oncology c
MNA | Jul 16, 2026, 07:29 PM UTC
L
Personalis Insider Sold Shares Worth $1,508,000, According to a Recent SEC Filing
() -- Christopher M Hall, Director, Chief Executive Officer, on July 09, 2026, sold 100,000 shares in Personalis (PSNL) for $1,508,000. Following the Form 4 filing with the SEC, Hall has control over a total of 235,986 c
REGULATION | Jul 10, 2026, 07:40 AM UTC
H
Personalis price target raised to $13 from $9 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm's price target on Personalis to $13 from $9 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 10:59 AM UTC